ML261 / Moonlight Bio - LARVOL DELTA

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Moonlight Bio, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Endocrine Cancer • Gastrointestinal Neuroendocrine Carcinoma • Genito-urinary Cancer • Genitourinary Neuroendocrine Carcinoma • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Pancreatic Cancer • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • DLL3

SPECTRAL-1: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Moonlight Bio, Inc

First-in-human • New P1 trial • Endocrine Cancer • Gastrointestinal Neuroendocrine Carcinoma • Genito-urinary Cancer • Genitourinary Neuroendocrine Carcinoma • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Pancreatic Cancer • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • DLL3